50BA

Bicycle Therapeutics DB:50BA Stock Report

Last Price

€25.80

Market Cap

€592.6m

7D

0%

1Y

-29.9%

Updated

14 Mar, 2023

Data

Company Financials +

50BA Stock Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics.

50BA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Bicycle Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bicycle Therapeutics
Historical stock prices
Current Share PriceUS$25.80
52 Week HighUS$39.20
52 Week LowUS$15.20
Beta0.77
1 Month Change1.57%
3 Month Change-11.03%
1 Year Change-29.89%
3 Year Changen/a
5 Year Changen/a
Change since IPO10.26%

Recent News & Updates

Recent updates

Shareholder Returns

50BADE BiotechsDE Market
7D0%-3.6%-4.1%
1Y-29.9%2.8%-9.5%

Return vs Industry: 50BA underperformed the German Biotechs industry which returned 2.8% over the past year.

Return vs Market: 50BA underperformed the German Market which returned -9.5% over the past year.

Price Volatility

Is 50BA's price volatile compared to industry and market?
50BA volatility
50BA Average Weekly Movement5.5%
Biotechs Industry Average Movement5.1%
Market Average Movement5.1%
10% most volatile stocks in DE Market9.4%
10% least volatile stocks in DE Market2.6%

Stable Share Price: 50BA is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 50BA's weekly volatility has decreased from 12% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009236Kevin Leehttps://www.bicycletherapeutics.com

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company’s oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4.

Bicycle Therapeutics plc Fundamentals Summary

How do Bicycle Therapeutics's earnings and revenue compare to its market cap?
50BA fundamental statistics
Market Cap€592.61m
Earnings (TTM)-€105.05m
Revenue (TTM)€13.48m

44.0x

P/S Ratio

-5.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
50BA income statement (TTM)
RevenueUS$14.46m
Cost of RevenueUS$81.61m
Gross Profit-US$67.15m
Other ExpensesUS$45.57m
Earnings-US$112.72m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.75
Gross Margin-464.26%
Net Profit Margin-779.35%
Debt/Equity Ratio11.2%

How did 50BA perform over the long term?

See historical performance and comparison